Evidence map›Paper›PMID 37111243›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Azithromycin and Sildenafil May Have Protective Effects on Retinal Ganglion Cells via Different Pathways: Study in a Rodent Microbead Model.

Tal Corina Sela, Alon Zahavi, Moran Friedman-Gohas, Shirel Weiss, Amir Sternfeld, Astrid Ilguisonis, Danielle Badash, Noa Geffen, Ron Ofri, Yaniv BarKana and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Multi-Target Neuroprotective Effects of Flavonoid-RichInternational journal of molecular sciences · 2025
    Article
  4. Article
  5. Immunomodulatory and Antioxidant Drugs in Glaucoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Tal Corina SelaClalit Health Services, Tel Aviv 6209804, Israel.ORCID 0000-0001-8077-7749
Alon ZahaviSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0002-9451-5253
Moran Friedman-GohasSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Shirel WeissSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-1724-3407
Amir SternfeldSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-2280-6163
Astrid IlguisonisKrieger Eye Research Laboratory, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Danielle BadashKrieger Eye Research Laboratory, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Noa GeffenSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Ron OfriKoret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot 7610001, Israel.ORCID 0000-0002-3825-3113
Yaniv BarKanaThe Glaucoma Innovations and Research Laboratory, The Sam Rothberg Glaucoma Center, Sheba Medical Center, Tel Hashomer 5262000, Israel.
Nitza Goldenberg-CohenKrieger Eye Research Laboratory, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.ORCID 0000-0002-5648-1873
Tel Aviv University · ILTechnion – Israel Institute of Technology · ILHebrew University of Jerusalem · ILSheba Medical Center · IL

Funding

CSRD VA 1
6 · The paper itself

Abstract

Decreased blood flow to the optic nerve (ON) and neuroinflammation are suggested to play an important role in the pathophysiology of glaucoma. This study investigated the potential neuroprotective effect of azithromycin, an anti-inflammatory macrolide, and sildenafil, a selective phosphodiesterase-5 inhibitor, on retinal ganglion cell survival in a glaucoma model, which was induced by microbead injection into the right anterior chamber of 50 wild-type (WT) and 30 transgenic toll-like receptor 4 knockout (TLR4KO) mice. Treatment groups included intraperitoneal azithromycin 0.1 mL (1 mg/0.1 mL), intravitreal sildenafil 3 µL, or intraperitoneal sildenafil 0.1 mL (0.24 μg/3 µL). Left eyes served as controls. Microbead injection increased intraocular pressure (IOP), which peaked on day 7 in all groups and on day 14 in azithromycin-treated mice. Furthermore, the retinas and ON of microbead-injected eyes showed a trend of increased expression of inflammatory- and apoptosis-related genes, mainly in WT and to a lesser extent in TLR4KO mice. Azithromycin reduced the BAX/BCL2 ratio, TGFβ, and TNFα levels in the ON and CD45 expression in WT retina. Sildenafil activated TNFα-mediated pathways. Both azithromycin and sildenafil exerted a neuroprotective effect in WT and TLR4KO mice with microbead-induced glaucoma, albeit via different pathways, without affecting IOP. The relatively low apoptotic effect observed in microbead-injected TLR4KO mice suggests a role of inflammation in glaucomatous damage.

Indexed as

azithromycinglaucomamicrobeadsneuroprotectionsildenafil

Identifiers

PMID37111243
PMCPMC10142588
OpenAlexW4361006663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.